List view / Grid view

Articles

Pharmaceutical QbD: Omnipresence in the product development lifecycle

18 April 2017 | By , ,

The concept of Quality by Design (QbD) was implemented by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and United States Food and Drug Administration (FDA) around a decade ago, with the aim of adopting systematic approaches for developing high-quality pharmaceutical products for patients’…

FMD and supply chain security

18 April 2017 | By

Over 12 months ago, the European Union delegated regulation that supplements the Falsified Medicines Directive (FMD) was published in the Official Journal of the European Union, starting the countdown to the deadline of 9 February 2019, when most EU member-states, and three non-members currently, are expected to have implemented all…

Microbiology In-Depth Focus 2017

13 April 2017 | By

In this Microbiology In-Depth Focus: Endotoxin masking hold-time study performance parameters; Microbiological monitoring pharmaceutical water systems; The rush to rapid microbiological methods - or not; and an expert view with Charles River Laboratories...

Alliance management organisational development: A Bayer perspective

4 April 2017 | By Christoph Huwe, Strategic Alliance Manager Therapeutics at Bayer Pharmaceuticals, Global External Innovation & Alliances

Ahead of the 7th Annual Strategic Alliance Management for Pharma conference, we spoke with Bayer's Christoph Huwe about the organisational development of alliance management...